Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer

We report our initial clinical experience with β -emitting (177)Lu-PSMA-I&T ((177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy) for systemic treatment of metastatic castration resistant prostate cancer. Patients with metastatic castration resistant prostate cancer...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of urology 2016-08, Vol.196 (2), p.382
Hauptverfasser:	Heck, Matthias M, Retz, Margitta, D'Alessandria, Calogero, Rauscher, Isabel, Scheidhauer, Klemens, Maurer, Tobias, Storz, Enno, Janssen, Friederike, Schottelius, Margret, Wester, Hans-Jürgen, Gschwend, Jürgen E, Schwaiger, Markus, Tauber, Robert, Eiber, Matthias
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - pathology Adenocarcinoma - radiotherapy Aged Antigens, Surface - therapeutic use Glutamate Carboxypeptidase II - therapeutic use Humans Ligands Lutetium - therapeutic use Male Middle Aged Neoplasm Metastasis Prostatic Neoplasms, Castration-Resistant - pathology Prostatic Neoplasms, Castration-Resistant - radiotherapy Radioisotopes - therapeutic use Radiopharmaceuticals - therapeutic use Retrospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!